Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated. Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythmâs MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the communityâs understanding of the ongoing impact and burden of disease on patients and caregivers. Source
No articles found.
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development a...
DelMar Pharmaceuticals is a biopharmaceutical c...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
Tivity Health, IncÂŽ is a leading provider of fitness and health improvement progr...
Tivity Health, IncÂŽ is a leading provider of f...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...
UroGen Pharma Ltd. is a clinical-stage biopharm...
Join the National Investor Network and get the latest information with your interests in mind.